Collegium Pharmaceutical Stock Performance
| COLL Stock | USD 37.30 0.28 0.76% |
On a scale of 0 to 100, Collegium Pharmaceutical holds a performance score of 6. The firm shows a Beta (market volatility) of 0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Collegium Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Collegium Pharmaceutical is expected to be smaller as well. Please check Collegium Pharmaceutical's downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Collegium Pharmaceutical's price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Collegium Pharmaceutical are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady essential indicators, Collegium Pharmaceutical disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 176.2 M |
Collegium |
Collegium Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 3,334 in Collegium Pharmaceutical on February 8, 2024 and sell it today you would earn a total of 396.00 from holding Collegium Pharmaceutical or generate 11.88% return on investment over 90 days. Collegium Pharmaceutical is currently generating 0.2046% in daily expected returns and assumes 2.3313% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Collegium, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Collegium Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Collegium Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Collegium Pharmaceutical, and traders can use it to determine the average amount a Collegium Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0878
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | COLL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.33 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Collegium Pharmaceutical is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Collegium Pharmaceutical by adding it to a well-diversified portfolio.
Collegium Pharmaceutical Fundamentals Growth
Collegium Stock prices reflect investors' perceptions of the future prospects and financial health of Collegium Pharmaceutical, and Collegium Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Collegium Stock performance.
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.41 % | ||||
| Current Valuation | 1.55 B | ||||
| Shares Outstanding | 32.71 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 5.98 X | ||||
| Price To Sales | 2.06 X | ||||
| Revenue | 566.77 M | ||||
| EBITDA | 331.83 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 674.28 M | ||||
| Debt To Equity | 3.82 % | ||||
| Book Value Per Share | 6.13 X | ||||
| Cash Flow From Operations | 274.75 M | ||||
| Earnings Per Share | 1.29 X | ||||
| Total Asset | 1.14 B | ||||
| Retained Earnings | (233.19 M) | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
About Collegium Pharmaceutical Performance
To evaluate Collegium Pharmaceutical Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Collegium Pharmaceutical generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Collegium Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Collegium Pharmaceutical market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Collegium's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Collegium Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 152 people.Things to note about Collegium Pharmaceutical performance evaluation
Checking the ongoing alerts about Collegium Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Collegium Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company currently holds 674.28 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Collegium Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Collegium Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Collegium Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Collegium to invest in growth at high rates of return. When we think about Collegium Pharmaceutical's use of debt, we should always consider it together with cash and equity. | |
| Over 99.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies |
- Analyzing Collegium Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Collegium Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Collegium Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Collegium Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Collegium Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Collegium Pharmaceutical's stock. These opinions can provide insight into Collegium Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Collegium Stock analysis
When running Collegium Pharmaceutical's price analysis, check to measure Collegium Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collegium Pharmaceutical is operating at the current time. Most of Collegium Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Collegium Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collegium Pharmaceutical's price. Additionally, you may evaluate how the addition of Collegium Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Collegium Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.